Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 2
1953 3
1954 2
1978 5
1979 2
1981 7
1982 2
1983 1
1984 3
1985 6
1986 3
1987 1
1988 3
1989 5
1990 7
1991 4
1992 3
1993 4
1994 6
1995 9
1996 4
1997 7
1998 13
1999 9
2000 5
2001 12
2002 15
2003 13
2004 7
2005 7
2006 4
2007 2
2008 2
2009 15
2010 10
2011 5
2012 8
2013 6
2014 6
2015 3
2016 5
2017 1
2018 1
2019 1
2020 4
2021 4
2022 2
2023 3
2024 2
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

242 results

Results by year

Filters applied: . Clear all
Page 1
Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.
Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, Mazieres J, Viteri S, Senellart H, Van Meerbeeck J, Raskin J, Reinmuth N, Conte P, Kowalski D, Cho BC, Patel JD, Horn L, Griesinger F, Han JY, Kim YC, Chang GC, Tsai CL, Yang JC, Chen YM, Smit EF, van der Wekken AJ, Kato T, Juraeva D, Stroh C, Bruns R, Straub J, Johne A, Scheele J, Heymach JV, Le X. Paik PK, et al. Among authors: scheele j. N Engl J Med. 2020 Sep 3;383(10):931-943. doi: 10.1056/NEJMoa2004407. Epub 2020 May 29. N Engl J Med. 2020. PMID: 32469185 Free PMC article. Clinical Trial.
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.
Wu YL, Cheng Y, Zhou J, Lu S, Zhang Y, Zhao J, Kim DW, Soo RA, Kim SW, Pan H, Chen YM, Chian CF, Liu X, Tan DSW, Bruns R, Straub J, Johne A, Scheele J, Park K, Yang JC; INSIGHT Investigators. Wu YL, et al. Among authors: scheele j. Lancet Respir Med. 2020 Nov;8(11):1132-1143. doi: 10.1016/S2213-2600(20)30154-5. Epub 2020 May 29. Lancet Respir Med. 2020. PMID: 32479794 Clinical Trial.
[Faecothorax].
Scheele J, Miksch T, Heller H, Sterk P. Scheele J, et al. Zentralbl Chir. 2010 Aug;135(4):340-1. doi: 10.1055/s-0030-1247243. Epub 2010 Aug 30. Zentralbl Chir. 2010. PMID: 20806137 German. No abstract available.
Late-life social activity.
Verkleij S, Scheele J, van der Wouden JC. Verkleij S, et al. Among authors: scheele j. Arch Intern Med. 2009 Nov 9;169(20):1931-2; author reply 1932. doi: 10.1001/archinternmed.2009.408. Arch Intern Med. 2009. PMID: 19901152 No abstract available.
Cystic teratoma of the pancreas.
Scheele J, Barth TF, Wittau M, Juchems M, Henne-Bruns D, Kornmann M. Scheele J, et al. Anticancer Res. 2012 Mar;32(3):1075-80. Anticancer Res. 2012. PMID: 22399635 Review.
Treatment of colorectal liver metastases.
Geoghegan JG, Scheele J. Geoghegan JG, et al. Among authors: scheele j. Br J Surg. 1999 Feb;86(2):158-69. doi: 10.1046/j.1365-2168.1999.01013.x. Br J Surg. 1999. PMID: 10100781 Review.
[Fungi in the mediastinum: rare, but relevant].
Kujath P, Scheele J, Esnaashari H, Shekarriz H, Bouchard R. Kujath P, et al. Among authors: scheele j. Mycoses. 2005;48 Suppl 1:18-21. doi: 10.1111/j.1439-0507.2005.01105.x. Mycoses. 2005. PMID: 15826282 Review. German.
242 results